UroGen Pharma
URGN

UroGen Pharma (URGN) earnings history

Most recent quarter

Period end
Sep 30, 2026
EPS actual
−$0.03
EPS surprise
−128.38%
Revenue
$89.0M
Reported
Nov 4, 2026

UroGen reported Q3 2026 results on November 4, 2026. It posted a loss of $0.03 per share, against an estimated profit of $0.11, a miss of 128.38%. Revenue was $89.0 million, just below the $89.9 million estimate by 1.02%. Compared with Q3 2025, the loss narrowed from $0.69 per share and revenue grew about 3.2 times from $27.5 million. UroGen posted a loss in each of the last 27 quarters. The annual loss narrowed from $5.92 per share in 2020 to $4.96 in 2021, $4.78 in 2022, $3.73 in 2023, $3.23 in 2024 and $3.20 in 2025. Annual revenue rose from $11.8 million in 2020 to $109.8 million in 2025. The first three quarters of 2026 add up to a loss of $0.78 per share, against $2.66 a year earlier, on revenue of $212.4 million, nearly three times the $72.0 million of the same period in 2025. Revenue has risen for six quarters in a row, and Q3 2026 brought both the highest revenue and the narrowest loss of the 27 quarters.

Q4 results came out between March 2 and March 22 in each of the past six years. That points to March 2027 for the Q4 2026 report.

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q3 2026Nov 4, 2026$0.11−$0.03−128.38%$89.0MSEC
Q2 2026Aug 5, 2026−$0.28−$0.28+0.00%$72.5MSEC
Q1 2026May 6, 2026−$0.48−$0.47+2.57%$51.0MSEC
Q4 2025Mar 2, 2026−$0.50−$0.54−7.48%$37.8MSEC
Q3 2025Nov 6, 2025−$0.69−$0.69+0.33%$27.5MSEC
Q2 2025Aug 7, 2025−$0.86−$1.05−21.43%$24.2MSEC
Q1 2025May 12, 2025−$0.80−$0.92−15.10%$20.3MSEC
Q4 2024Mar 10, 2025−$0.72−$0.80−11.16%$24.6MSEC
Q3 2024Nov 6, 2024−$0.82−$0.55+32.69%$25.2MSEC
Q2 2024Aug 13, 2024−$0.83−$0.91−9.38%$21.8MSEC
Q1 2024May 13, 2024−$0.87−$0.97−11.93%$18.8MSEC
Q4 2023Mar 14, 2024−$0.68−$0.72−5.88%$23.5MSEC
Q3 2023Nov 14, 2023−$0.85−$0.68+19.62%$20.9MSEC
Q2 2023Aug 10, 2023−$1.14−$1.03+9.33%$21.1MSEC
Q1 2023May 11, 2023−$1.33−$1.30+2.26%$17.2MSEC
Q4 2022Mar 22, 2023−$1.07−$1.22−13.67%$18.1MSEC
Q3 2022Nov 10, 2022−$1.16−$1.13+2.31%$16.1MSEC
Q2 2022Aug 11, 2022−$1.28−$1.18+7.45%$16.6MSEC
Q1 2022May 10, 2022−$1.33−$1.25+6.25%$13.6MSEC
Q4 2021Mar 21, 2022−$1.18−$1.27−8.09%$16.2MSEC

Quarterly revenue

Q4 2021
$16.2M
Q1 2022
$13.6M
Q2 2022
$16.6M
Q3 2022
$16.1M
Q4 2022
$18.1M
Q1 2023
$17.2M
Q2 2023
$21.1M
Q3 2023
$20.9M
Q4 2023
$23.5M
Q1 2024
$18.8M
Q2 2024
$21.8M
Q3 2024
$25.2M
Q4 2024
$24.6M
Q1 2025
$20.3M
Q2 2025
$24.2M
Q3 2025
$27.5M
Q4 2025
$37.8M
Q1 2026
$51.0M
Q2 2026
$72.5M
Q3 2026
$89.0M

Frequently asked questions

  • When did UroGen Pharma (URGN) last report earnings?

    UroGen Pharma last reported on Nov 4, 2026, covering fiscal Q3 2026.

  • Did URGN beat earnings estimates?

    No. UroGen Pharma reported EPS of −$0.03 for Q3 2026 against a $0.11 estimate — a 128.38% miss.

  • How much revenue did URGN report last quarter?

    UroGen Pharma reported $89.0M in revenue for Q3 2026, against a consensus estimate of $89.9M.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.